Trending Stock News

Sivik Global Healthcare Cut Its Acadia Pharm (ACAD) Position by $1.65 Million; Needham Investment Management Decreased Schlumberger LTD (SLB) Position by $502,500 as Valuation Declined

Schlumberger Limited (NYSE:SLB) Logo

Krishen Sud decreased its stake in Acadia Pharm (ACAD) by 45.83% based on its latest 2017Q4 regulatory filing with the SEC. Sivik Global Healthcare Llc sold 55,000 shares as the company’s stock declined 22.49% with the market. The hedge fund run by Krishen Sud held 65,000 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.96M, down from 120,000 at the end of the previous reported quarter. Sivik Global Healthcare Llc who had been investing in Acadia Pharm for a number of months, seems to be less bullish one the $2.31B market cap company. The stock decreased 0.43% or $0.08 during the last trading session, reaching $18.5. About 2.30M shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 36.38% since May 17, 2017 and is downtrending. It has underperformed by 47.93% the S&P500.

Needham Investment Management Llc decreased its stake in Schlumberger Ltd (SLB) by 60% based on its latest 2017Q4 regulatory filing with the SEC. Needham Investment Management Llc sold 7,500 shares as the company’s stock declined 4.39% with the market. The institutional investor held 5,000 shares of the oilfield services and equipment company at the end of 2017Q4, valued at $337,000, down from 12,500 at the end of the previous reported quarter. Needham Investment Management Llc who had been investing in Schlumberger Ltd for a number of months, seems to be less bullish one the $101.27 billion market cap company. The stock increased 2.11% or $1.51 during the last trading session, reaching $73.11. About 7.12M shares traded or 1.87% up from the average. Schlumberger Limited (NYSE:SLB) has declined 16.28% since May 17, 2017 and is downtrending. It has underperformed by 27.83% the S&P500.

Investors sentiment decreased to 0.66 in Q4 2017. Its down 0.22, from 0.88 in 2017Q3. It worsened, as 90 investors sold SLB shares while 672 reduced holdings. 140 funds opened positions while 365 raised stakes. 1.05 billion shares or 11.89% less from 1.20 billion shares in 2017Q3 were reported. Murphy Cap Mgmt Inc reported 0.29% in Schlumberger Limited (NYSE:SLB). Palo Incorporated reported 8,582 shares. Cadence Capital Limited Liability Company invested 0.63% of its portfolio in Schlumberger Limited (NYSE:SLB). Thomas White Limited holds 0.14% or 12,379 shares in its portfolio. Parametric Portfolio Associates Lc holds 2.33 million shares. Comerica Secs Inc reported 24,188 shares. Duncker Streett & holds 0.19% of its portfolio in Schlumberger Limited (NYSE:SLB) for 10,990 shares. Georgia-based Crawford Counsel has invested 0.04% in Schlumberger Limited (NYSE:SLB). Advsr Inc Ok holds 7,110 shares or 0.03% of its portfolio. Fruth Inv Management holds 14,203 shares. 235,664 are held by Arosa Capital Mngmt L P. Carroll Financial Associates accumulated 7,558 shares. Valicenti Advisory Service accumulated 58,347 shares. Kj Harrison Prtn Incorporated holds 0.15% of its portfolio in Schlumberger Limited (NYSE:SLB) for 6,730 shares. Moreover, Altfest L J & Communications has 0.09% invested in Schlumberger Limited (NYSE:SLB) for 3,563 shares.

More recent Schlumberger Limited (NYSE:SLB) news were published by: Seekingalpha.com which released: “Schlumberger Keeps Chugging Along” on April 23, 2018. Also Seekingalpha.com published the news titled: “Stay Away From Apple Component Players – Cramer’s Lightning Round (5/16/18)” on May 17, 2018. 247Wallst.com‘s news article titled: “Why Schlumberger’s Earnings Beat Isn’t Helping the Stock” with publication date: April 20, 2018 was also an interesting one.

Since January 22, 2018, it had 3 insider buys, and 2 sales for $6.71 million activity. $323,950 worth of Schlumberger Limited (NYSE:SLB) shares were bought by Schorn Patrick. $5.91M worth of Schlumberger Limited (NYSE:SLB) shares were sold by AYAT SIMON. KIBSGAARD PAAL bought $646,800 worth of Schlumberger Limited (NYSE:SLB) on Monday, March 26. 3,000 Schlumberger Limited (NYSE:SLB) shares with value of $192,900 were bought by Al Mogharbel Khaled.

Analysts await Schlumberger Limited (NYSE:SLB) to report earnings on July, 20. They expect $0.46 EPS, up 31.43% or $0.11 from last year’s $0.35 per share. SLB’s profit will be $637.16 million for 39.73 P/E if the $0.46 EPS becomes a reality. After $0.38 actual EPS reported by Schlumberger Limited for the previous quarter, Wall Street now forecasts 21.05% EPS growth.

Among 39 analysts covering Schlumberger Limited. (NYSE:SLB), 32 have Buy rating, 1 Sell and 6 Hold. Therefore 82% are positive. Schlumberger Limited. had 148 analyst reports since July 22, 2015 according to SRatingsIntel. Nomura maintained Schlumberger Limited (NYSE:SLB) on Tuesday, August 16 with “Buy” rating. Susquehanna maintained the shares of SLB in report on Monday, January 22 with “Buy” rating. The firm earned “Buy” rating on Thursday, August 27 by Argus Research. Morgan Stanley maintained it with “Overweight” rating and $105 target in Tuesday, April 19 report. The company was maintained on Thursday, January 11 by Cowen & Co. The stock of Schlumberger Limited (NYSE:SLB) has “Market Perform” rating given on Wednesday, October 11 by BMO Capital Markets. The stock of Schlumberger Limited (NYSE:SLB) earned “Outperform” rating by Credit Suisse on Monday, April 4. The rating was maintained by Seaport Global with “Buy” on Monday, January 22. The rating was maintained by Morgan Stanley with “Overweight” on Monday, October 23. On Monday, May 23 the stock rating was upgraded by Goldman Sachs to “Conviction Buy”.

More important recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: Seekingalpha.com which released: “Acadia: Damn The Torpedoes, Full Speed Ahead” on May 07, 2018, also Fool.com published article titled: “This Explains Why Acadia Pharmaceuticals Is Selling Off Today”, Streetinsider.com published: “UPDATE: Acadia Pharma (ACAD) Quickly Falls to Session Low on Report FDA to Reexamine Nuplazid” on April 25, 2018. More interesting news about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was released by: Seekingalpha.com and their article: “Acadia stands behind risk/benefit profile of Nuplazid; shares up 4% premarket” with publication date: April 27, 2018.

Since January 2, 2018, it had 1 buy, and 3 sales for $3.94 million activity. 25,000 shares were sold by Brege Laura, worth $751,543. $234,910 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was bought by SOLAND DANIEL B.

Investors sentiment increased to 1.26 in 2017 Q4. Its up 0.25, from 1.01 in 2017Q3. It increased, as 30 investors sold ACAD shares while 47 reduced holdings. 32 funds opened positions while 65 raised stakes. 117.35 million shares or 3.35% more from 113.55 million shares in 2017Q3 were reported. Point72 Asia (Hong Kong) reported 481 shares stake. 106 were accumulated by Brown Brothers Harriman And. Federated Investors Pa accumulated 70,088 shares. Qs Investors Ltd Limited Liability Company owns 1,817 shares. Envestnet Asset Management owns 318 shares for 0% of their portfolio. Gilder Gagnon Howe Communications has 0.05% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 112,626 shares. Group Incorporated One Trading Limited Partnership owns 133,080 shares or 0.03% of their US portfolio. Credit Suisse Ag holds 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 83,485 shares. Rhumbline Advisers owns 108,360 shares for 0.01% of their portfolio. Frontier Capital Management Limited Liability Corp reported 0.02% stake. Alyeska Group LP invested 0.17% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Fred Alger owns 2.17M shares for 0.29% of their portfolio. Price T Rowe Associates Md holds 812,627 shares. Eventide Asset Management Limited Liability Corporation holds 0.53% or 334,700 shares in its portfolio. Citigroup accumulated 73,031 shares.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on August, 14. They expect $-0.46 earnings per share, up 16.36% or $0.09 from last year’s $-0.55 per share. After $-0.44 actual earnings per share reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.

Sivik Global Healthcare Llc, which manages about $250.21M and $269.45M US Long portfolio, upped its stake in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 15,000 shares to 40,000 shares, valued at $1.95M in 2017Q4, according to the filing. It also increased its holding in Catalent Inc (NYSE:CTLT) by 33,600 shares in the quarter, for a total of 75,000 shares, and has risen its stake in Express Scripts Holding Company Com (NASDAQ:ESRX).

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals had 35 analyst reports since August 7, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 8 report. As per Thursday, August 27, the company rating was upgraded by Piper Jaffray. The rating was maintained by Cowen & Co with “Buy” on Tuesday, November 7. On Wednesday, October 19 the stock rating was reinitiated by Roth Capital with “Neutral”. The stock has “Buy” rating by Jefferies on Tuesday, October 10. The rating was maintained by Needham on Friday, August 7 with “Buy”. The rating was maintained by Cowen & Co with “Outperform” on Sunday, August 9. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 9 report. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Jefferies given on Monday, June 26.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *